(Received for publication, December 14, 1961) 2) 17-OHCS excretion in urine Urinary excretion of 17-OHCS ranges 4.5 to 8.0 mg. daily in non-diabetic controls1B). The average urinary excretions of 17-OHCS before therapy were 7.9 and 10.0 mg. daily in type I and type II diabetics, respectively. In type I diabetics, 42.5 per cent of them had a higher level of urinary 17-OHCS excretion than normal, 37.5 per cent of them had normal amount and 20.0 per cent of them had a lower level. In type II diabetics, 55.5 per cent of them were distributed in the higher range, 36.5 per cent of them in the normal range and only 8.0 per cent of them in the lower range as compared with the control subjects.
Concerned with the changes of urinary 17-OHCS following therapy, the mean value of five type I diabetics was 8.1 mg. daily after treatment, while the mean value of twenty type II diabetics decreased to 5.5 mg. daily during treatment and was 5.2 mg. daily after therapy (TABLE II) . In eleven type II diabetics, when fairly controlled, a marked decrease in urinary excretion of 17-OHCS was especially noted. However, no significant correlation was observed between the fasting blood sugar level and urinary excretion of 17-OHCS.
3) Urinary excretion of 17-KS Urinary 17-KS is excreted 5 to 10 mg. daily in normal subjects". The average excretion of 17-KS in either type of diabetics was within normal range before therapy, 7.7 mg. daily in thirty type I diabetics, 8.2 mg. daily in fifty-four type II diabetics (TABLE III) .
As to 17-KS excretion before treatment, in type I diabetics 10 per cent of them were in the higher level, 80 per cent of them in the normal range and 10 per cent of them in the lower level as compared with the normal controls, while in type II diabetics 35.2 per cent of them were distributed in the higher level, 40.7 per cent of them in the normal range and 24.1 per cent in the lower level.
The average excretion for five type I diabetics was 7.7 mg. daily after There have been numerous reports on the function of the adrenal cortex in diabetics but they have not always been in full agreement. Lowered function of the adrenal cortex has been described by Forbes et al. ,21) Field and Marble,22) Wolfe and Paschkis23) and Talbot and his co-workers.24) Miller and Mason251 and On026) reported the absence of any definite results on the function of the adrenal cortex. Hyperfunction of the adrenal cortex, however, was reported by Klein and his co-workers, 21) Oj i21) and Matsui. 29) Such varied results might be due to the several factors. 1) It is generally accepted that diabetes mellitus is not a single clinical entity but a syndrome. Diabetes mellitus includes several types and can be classified as juvenile or adult type, thin or obese, non-requiring insulin or requiring insulin, and so on. Therefore, it is natural that results should vary un reporting the function of the adrenal cortex unless closer consideration is given to the types of diabetes mellitus.
2) The adrenal gland may possibly represent the response to various diabetic states, such as controlled or uncontrolled, acidosis or non-acidosis, stable or brittle.
3) An increased excretion of urinary 17-OHCS has been reported in diabetic patients complicated with retinopathy, nephropathy or cardiovascular lesions by Becker,30) Maengwyn-Davies and his co-workers31) and Saito and his coworkers.18) To summarize the results obtained in our study, the hyperfunction of the adrenal cortex was observed in many cases of diabetics especially in cases diagnosed as severe before treatment. These accentuated adrenocortical func tions were normalized when good control was obtained by treatment, while they remained high when the diabetic state unfortunately had not improved.
Is the hyperfunction of the adrenal cortex the cause or the consequence of diabetes mellitus? Warren32) stated that no constant gross or microscopic changes in the adrenals were observed in autopsy and that any changes encountered in the adrenals might represent the non-specific response to the stress of the diabetic state, rather than having any primary etiological significance.
It is well known that acidosis and hyperglycemia are the most important causes among the diabetic states which stimulate the pituitary-adrenal system.
There have been numerous reports that urinary excretion of ketosteroid or the plasma content of hydroxycorticosteroid is increased at the diabetic acidosis.33 )34135)36) Ono26) reported that hyperfunction of the adrenal cortex was produced secondarily by metabolic disorder without hyperglycemia. A marked increased excretion of 17-KS in urine and a decrease in eosinophil cells in blood were observed in twelve out of thirteen normal subjects or the patients uncomplicated with endocrine disorders, who were administered a lowcarbohydrate, high-protein and high-fat diet for two days. On the other hand, many reports have been described by Jordan 311, Frey and Tecklenborg38) and Artunkal and Kayahan39) that a decrease in eosinophil cell count in blood was observed following glucose administration.
Yoshida,40) in our Department, observed an increased excretion of 17-KS following the administration of 50 g. of glucose in diabetics as compared with normal subjects.
In our study, hyperfunction of the adrenal cortex was observed in diabetics whose fasting blood sugar was more than 200 mg. per dl., although a significant correlation was not always found between fasting blood sugar and the function tests of the adrenal cortex. Therefore, the results obtained in this study suggest that the hyperfunction of the adrenal cortex is the consequence of a diabetic state especially hyperglycemia and/or acidosis.
It remains to be explained whether hyperfunction of the adrenal cortex plays a part in the occurrence of diabetes mellitus, because the results obtained in our study were observed in the diabetic patients and not in prediabetics .
White41) and Bjorklund and Jensen42) reported that an increased excretion of 17-KS was observed in children from diabetic parents. Kato,4s) in our Depart ment, described an increased urinary excretion of 17-KS in the relatives of diabetics. The hyperfunction of the pituitary-adrenal system was proved histo logically by Saito and his co-workers44) in rats, which were fed on a high-protein high-fat diet and revealed a decreased glucose tolerance. Okamoto and his co-workers45 ) reported that increased excretions of urinary 17-OHCS, 17-KS, its VI and VII fractions, uropepsin and gonadotropin were observed in experi mental hereditary diabetic animals which had a diabetic state.
The works cited above suggest that the pituitary-adrenal gland system may play a part in etiology of diabetes mellitus. Therefore, it is suggested that a diabetic state and the hyperfunction of the adrenal cortex might form a vicious circle which would be interrupted by appropriate treatment.
The most striking thing in this study on the adrenomedullary function is the fact that diabetics of both type I and type II had a decreased content of urinary adrenaline, although transient increase of adrenaline in the urine was observed during the insulin treatment in type II diabetics.
There was no evidence of a low content of adrenaline in the adrenal medulla of diabetes mellitus because of the fact that a sufficient response of adrenaline excretion was observed in diabetics following insulin administration as compared with control subjects.46) It is supposed that the methylation of noradrenaline to adrenaline was not impaired in diabetics, because there was no significant increase in urinary noradrenaline excretion for diabetics as compared with the control subjects. Luft and Euler47) have reported that ACTH and cortisone were related to the formation and secretion of noradrenaline, but had no action to inhibit adrenaline secretion from the adrenal gland. E1y,48) Sandberg,49) Kelley50) and Kinsell51) have also reported that there was no direct interaction between adrenaline and the steroid hormone. Therefore, it is not considered that a decreased excretion in urinary adrenaline in diabetics was due to the hyperfunc tion of the pituitary-adrenal system, which was observed in numerous diabetics in our study. In diabetics there was no significant correlation between resting excretion of urinary adrenaline and fasting blood sugar, although the resting excretion level of urinary adrenaline in diabetics with high fasting blood sugar was lower than that in the non-diabetics. Urinary excretion of adrenaline was significantly decreased in diabetics following the administration of glucose as compared with the control subjects.46 A decreased excretion of urinary adrenal ine might be explained as being related to the increased deviation in postprandial blood sugar or decreased glucose tolerance.
SUNIMARY
The fluctuation of the function of the adrenal gland, both cortex and medulla, after treatment was observed in diabetics admitted to our Department.
The average content of 17-OHCS in plasma was within the normal range before treatment and was not changed after treatment in type I diabetics, while it was higher than the normal range before treatment and decreased after treament in type II diabetics. The average excretions of urinary 17-OHCS before therapy were 7.9 and 10.0 mg. daily in type I and type II diabetics, respectively, whereas after therapy they were 8.1 and 5.2 mg. per day in type I and type II diabetics, respectively. A decreased excretion of urinary 17-OHCS was found especially in type II diabetics when well controlled.
The average excretion of 17-KS in urine was within the normal range before treatment in both types of diabetics. Higher value of urinary excretion of 17-KS was observed in 10 per cent out of thirty type I diabetics and 35 per cent out of fifty-four type II diabetics. After treatment, the average urinary excretions of 17-KS were 7.7 and 7.4 mg. per day, respectively.
The average excretion of uropepsin in type I diabetics before treatment was 273 micrograms per hour, decreasing to 218 micrograms after treatment. It was 388 micrograms in type II diabetics before treatment and markedly decreased to 261 micrograms after therapy.
The eosinophil cells in blood were within the normal range and were markedly reduced in five out of thirty-one type I diabetics and twelve out of thirty type II diabetics before treatment. They decreased only in one out of seven type I and three out of ten type II diabetics after treatment.
The response of eosinophil cells to the administration of ACTH-Z was within the normal range in both diabetic types before and after treatment.
The urinary excretion of adrenaline in diabetics was significantly decreased as compared with the normal subjects. The mean values were 5.5 and 4.7 micrograms daily in type I and type II diabetics, respectively. They remained to be low after treatment, 6.2 and 4.3 micrograms per day in type I and type II diabetics, respectively.
The mean values of urinary noradrenaline excretion in diabetics remained within the normal range before treatment and they did not fluctuate after therapy.
The hyperfunction of the adrenal cortex and a decreased excretion of urinary adrenaline in diabetics were discussed.
